Cove Behavioral Health will give patients with opioid use disorder access to Pear's reSET-O via a State Opioid Response (SOR) funding
The deal will give access to innovative treatment options to fight against the addiction crisis. (Credit: Pexels from Pixabay)
US-based Pear Therapeutics and Cove Behavioral Health have announced a partnership under which Cove will provide access to Pear’s FDA-cleared PDT reSET-O for the treatment of opioid use disorder (OUD).
Cove, a substance use disorder service provider, intends to implement reSET-O in its centres in Tampa Bay, Florida for eligible patients.
Pear Therapeutics said that people in need of prevention, treatment, and recovery support for OUD are eligible for funding through the State Opioid Response (SOR) grant programme.
The programme is managed by Central Florida Behavioral Health Network and is part of the U.S. Department of Health and Human Services’ Substance Abuse and Mental Health Services Administration (SAMHSA).
According to Pear, the reSET-O is an innovative product to tackle the current opioid crisis in America.
It will offer cognitive behavioural therapy, as an adjunct to outpatient treatment for patients 18 years or older who are currently under the supervision of a clinician.
By making reSET-O available in Spanish, Cove, which annually provides treatment, prevention, education, and outreach to around 30,000 members of the Tampa Bay region, will support its Hispanic patients.
Behavioral Health chief executive officer Deanna Obregon said: “We are proud to partner with the Department of Children and Families & Central Florida Behavioral Health Network to explore ways to better serve our patients.
“The reSET-O digital therapeutic pilot project focuses on helping our patients engage in treatment and improve patient outcomes.”
PDTs are a new treatment category that employs computer software to treat critical diseases. They gather real-world data for use by prescribing clinicians as well as for population health management by payors and health systems.
Pear chief commercial officer Julia Strandberg said: “Pear is excited to team with Cove at a time when it’s more important than ever to provide people with OUD access to evidence-based treatments.
“Our PDTs are innovative, FDA-authorised therapeutics designed to be used remotely anytime, anywhere by patients. We believe that Cove and Pear can help expand access to care and benefit patients in recovery.”